Beneficial Impact of Vaccination Against SARS-CoV-2 on the Mental Health of IPF Patients
Tomos I, Papaioannou A, Daniil Z, Dimeas I, Kirgou P, Gogali A, Tatsis K, Papanikolaou I, Tzilas V, Tzouvelekis A, Tsiri P, Steiropoulos P, Ntolios P, Xyfteri A, Antoniou K, Symvoulakis E, Haritou A, Maniati M, Kolilekas L, Antonogiannaki E, Apollonatou V, Kallieri M, Samaras K, Loukides S, Karakatsani A, Bouros D, Manali E, Papiris S. Beneficial Impact of Vaccination Against SARS-CoV-2 on the Mental Health of IPF Patients. Advances In Respiratory Medicine 2024, 92: 466-471. DOI: 10.3390/arm92060042.Peer-Reviewed Original ResearchHospital Anxiety and Depression ScaleHospital Anxiety and Depression Scale scoresHistory of depressionDepression ScaleMental healthAnxiety and Depression ScaleIndependent of ageGlobal mental healthDepression Scale scoresLung function impairmentFunctional impairmentQuality of lifeWilcoxon signed rank testIdiopathic pulmonary fibrosis patientsIdiopathic pulmonary fibrosisCOVID-19Scale scoreDepressionAnxietyCOVID-19 pandemicAnxiety disordersSmokingFollowed-upHospitalRank testInterstitial Lung Diseases and Non-Small Cell Lung Cancer: Particularities in Pathogenesis and Expression of Driver Mutations
Sampsonas F, Bosgana P, Bravou V, Tzouvelekis A, Dimitrakopoulos F, Kokkotou E. Interstitial Lung Diseases and Non-Small Cell Lung Cancer: Particularities in Pathogenesis and Expression of Driver Mutations. Genes 2024, 15: 934. PMID: 39062713, PMCID: PMC11276289, DOI: 10.3390/genes15070934.Peer-Reviewed Original ResearchConceptsInterstitial lung diseaseLung cancerLung diseaseDriver mutationsImproved survivalTreatment optionsChronic inflammationPathogenetic pathwaysNon-small cell lung cancerConcurrent interstitial lung diseaseCell lung cancerSites of chronic inflammationAnti-fibrotic medicationsCurrent treatment optionsIdiopathic pulmonary fibrosisDiseases associated with chronic inflammationIncidence of lung cancerPersonalized medicine approachPrompt diagnosisClinical entityNon-smallPulmonary fibrosisNSCLCSurvival ratePatientsModified blood cell GAP model as a prognostic biomarker in idiopathic pulmonary fibrosis
Kreuter M, Lee J, Tzouvelekis A, Oldham J, Molyneaux P, Weycker D, Atwood M, Samara K, Kirchgässler K, Maher T. Modified blood cell GAP model as a prognostic biomarker in idiopathic pulmonary fibrosis. ERJ Open Research 2024, 10: 00666-2023. PMID: 39076530, PMCID: PMC11284599, DOI: 10.1183/23120541.00666-2023.Peer-Reviewed Original ResearchIdiopathic pulmonary fibrosisWhite blood cellsRed blood cellsNeutrophil countMonocyte countPulmonary fibrosisHemoglobin levelsRandomised phase III trialBaseline white blood cellC-statisticIPF outcomesBlood cellsTrials of pirfenidoneIdiopathic pulmonary fibrosis progressionImprove prediction of outcomeRed blood cell variablesBlood cell countPredictive of outcomeStudy outcomesRed blood cell parametersMortality prediction toolRespiratory-related hospitalisationEosinophil countRetrospective analysisMultivariate analysis